Advancements in Treatment of PH-Negative ALL for Younger Patients

In the podcast, the speaker discusses the advancements in the treatment of Philadelphia-negative acute lymphoblastic leukemia (ALL) for younger patients. They highlight the use of targeted therapies, including TKIs and immunotherapy, in combination with low-dose chemotherapy. This approach has shown significant improvements in survival rates, with four-year survival reaching 82%. The speaker also emphasizes the importance of measuring minimal residual disease (MRD) using flow cytometry and NGS to assess disease response, guiding treatment decisions. They mention ongoing studies to further explore the role of immunotherapy upfront and reduce chemotherapy in the management of ALL.